Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Therapies02:49

Cancer Therapies

10.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.8K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for investigating STAT3 regulation of lysosomal function in mammary epithelial cells.

Journal of mammary gland biology and neoplasia·2024
Same author

Alveolar cells in the mammary gland: lineage commitment and cell death.

The Biochemical journal·2022
Same author

The immune environment of the mammary gland fluctuates during post-lactational regression and correlates with tumour growth rate.

Development (Cambridge, England)·2022
Same author

Gpr125 is a unifying hallmark of multiple mammary progenitors coupled to tumor latency.

Nature communications·2022
Same author

The ever-expanding landscape of cancer therapeutic approaches.

The FEBS journal·2021
Same author

In conversation with Christine Watson.

The FEBS journal·2021

Related Experiment Video

Updated: Apr 15, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.7K

STAT3 the oncogene - still eluding therapy?

Matthew S Wake1, Christine J Watson1

  • 1Department of Pathology, University of Cambridge, UK.

The FEBS Journal
|April 1, 2015
PubMed
Summary

Signal transducer and activator of transcription 3 (STAT3) is crucial in cancer development and progression. Inhibiting STAT3 activity shows promise as a cancer therapeutic strategy, though clinical inhibitors are still under development.

Keywords:
STAT3cancercancer therapeuticsinhibitorssignallingtumourigenesis

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.9K

Related Experiment Videos

Last Updated: Apr 15, 2026

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts
11:19

Merging Absolute and Relative Quantitative PCR Data to Quantify STAT3 Splice Variant Transcripts

Published on: October 9, 2016

15.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors
19:02

High-Efficiency Transduction of Liver Cancer Cells by Recombinant Adeno-Associated Virus Serotype 3 Vectors

Published on: March 22, 2011

13.9K

Area of Science:

  • Molecular Biology
  • Oncology
  • Cellular Signaling

Background:

  • Signal transducers and activators of transcription (STATs) are key mediators of cytokine signaling.
  • STAT3 is widely activated by various factors and plays critical roles in physiological processes.
  • Aberrant STAT3 activation is implicated in numerous solid and liquid tumors, promoting tumorigenesis.

Purpose of the Study:

  • To review the role of STAT3 in tumorigenesis.
  • To discuss the potential of STAT3 as a therapeutic target for cancer treatment.

Main Methods:

  • Literature review of STAT3's function in cancer.
  • Analysis of STAT3's role in gene regulation (cell cycle, angiogenesis, apoptosis).
  • Examination of STAT3's paradoxical role in cell death induction.

Main Results:

  • STAT3 promotes tumor growth by regulating oncogenic genes.
  • STAT3 signaling can paradoxically induce cell death in specific contexts.
  • STAT3 inhibition demonstrably reduces tumor growth and survival in preclinical studies.

Conclusions:

  • STAT3 is a significant driver of tumorigenesis.
  • Targeting STAT3 presents a promising strategy for cancer therapy.
  • Development of effective clinical STAT3 inhibitors remains an ongoing challenge.